Towards developing biomarkers for glioblastoma multiforme: A proteomics view

Expert Review of Proteomics

Volumn 11, Issue 5, 2014, Pages 621-639

  Jayaram, Savita ^a,b   Gupta, Manoj Kumar ^a,b   Polisetty, Ravindra Varma ^a   Cho, William C S ^c   Sirdeshmukh, Ravi ^a,d  

^a Institute of Bioinformatics   (India)

^b MANIPAL UNIVERSITY   (India)

^c QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^d Narayana Health City   (India)

Author keywords

biomarker; cerebrospinal fluid; glioblastoma; mass spectrometry; plasma; proteomics; secretome

Indexed keywords

BIOLOGICAL MARKER; PROTEIN; PROTEOME; TRANSCRIPTOME; TUMOR MARKER;

BIOINFORMATICS; BLOOD ANALYSIS; BRAIN TUMOR; CANCER TISSUE; EXOSOME; GENOMICS; GLIOBLASTOMA; HUMAN; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEOMICS; REVIEW; TISSUE TYPING; TRANSCRIPTOMICS; TUMOR MICROENVIRONMENT; ANIMAL; BLOOD; CEREBROSPINAL FLUID; METABOLISM;

ANIMALS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; PROTEOME; PROTEOMICS; TRANSCRIPTOME; TUMOR MICROENVIRONMENT;

EID: 84907261025     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2014.939634     Document Type: Review

References (119)

1. DeAngelis LM. Brain tumors. N Engl J Med 2001;344(2):114-23
2. Maher EA, Furnari FB, Bachoo RM, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15(11): 1311-33
3. Rothstein JD. Paving new pathways. Nat Med 2002;8(9):938-40
4. Sontheimer H. A role for glutamate in growth and invasion of primary brain tumors. J Neurochem 2008;105(2):287-95
5. Westermark B. Glioblastoma-A moving target. Ups J Med Sci 2012;117(2):251-6
6. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007;21(21):2683-710
7. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9(3): 157-73
8. Maher EA, Brennan C, Wen PY, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res 2006; 66(23):11502-13
9. Sanai N. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma. World Neurosurg 2010;74(1): 4-5
10. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17(1):98-110
11. Chin L, Meyerson M. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-8
12. Rao RD, James CD. Altered molecular pathways in gliomas: An overview of clinically relevant issues. Semin Oncol 2004; 31(5):595-604
13. Agnihotri S, Burrell KE, Wolf A, et al. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp (Warsz) 2013;61(1):25-41
14. Riddick G, Fine HA. Integration and analysis of genome-scale data from gliomas. Nat Rev Neurol 2011;7(8):439-50
15. Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 2013; 110(10):4009-14
16. Ilhan-Mutlu A, Wagner L, Preusser M. Circulating biomarkers of CNS tumors: An update. Biomark Med 2013;7(2):267-85
17. Kalinina J, Peng J, Ritchie JC, Van Meir EG. Proteomics of gliomas: initial biomarker discovery and evolution of technology. Neuro Oncol 2011;13(9): 926-42
18. Somasundaram K, Nijaguna MB, Kumar DM. Serum proteomics of glioma: methods and applications. Expert Rev Mol Diagn 2009;9(7):695-707
19. Sirdeshmukh R, Santosh V, Srikanth A. Differential protein expression, protein profiles of human gliomas and clinical implications. In: Appasani K, editor. Bio arrays: from basics to diagnostics. Humana Press; Totowa, NJ, USA: 2006. p. 145-69
20. Gupta MK, Polisetty RV, Ramamoorthy K, et al. Secretome analysis of Glioblastoma cell line-HNGC-2. Mol Biosyst 2013;9(6): 1390-400
21. Polisetty RV, Gupta MK, Nair SC, et al. Glioblastoma cell secretome: Analysis of three glioblastoma cell lines reveal 148 non-redundant proteins. J Proteomics 2011;74(10):1918-25
22. Weeraphan C, Diskul-Na-Ayudthaya P, Chiablaem K, et al. Effective enrichment of cholangiocarcinoma secretomes using the hollow fiber bioreactor culture system. Talanta 2012;99:294-301
23. Mathivanan S, Lim JW, Tauro BJ, et al. Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol Cell Proteomics 2010;9(2):197-208
24. Shao H, Chung J, Balaj L, et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med 2012;18(12):1835-40
25. Simpson RJ, Kalra H, Mathivanan S. ExoCarta as a resource for exosomal research. J Extracell Vesicles 2012;1
26. Ross PL, Huang YN, Marchese JN, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004;3(12):1154-69
27. Gautam P, Nair SC, Gupta MK, et al. Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis. PLoS ONE 2012;7(9):e46153
28. Gollapalli K, Ray S, Srivastava R, et al. Investigation of serum proteome alterations in human glioblastoma multiforme. Proteomics 2012;12(14):2378-90
29. Lin Q, Tan HT, Lim HS, Chung MC. Sieving through the cancer secretome. Biochim Biophys Acta 2013;1834(11): 2360-71
30. Marimuthu A, Subbannayya Y, Sahasrabuddhe NA, et al. SILAC-based quantitative proteomic analysis of gastric cancer secretome. Proteomics Clin Appl 2013;7(5-6):355-66
31. James A, Jorgensen C. Basic design of MRM assays for peptide quantification. Methods Mol Biol 2010;658:167-85
32. Mischel PS, Cloughesy TF, Nelson SF. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 2004;5(10):782-92
33. Kim S, Dougherty ER, Shmulevich I, et al. Identification of combination gene sets for glioma classification. Mol Cancer Ther 2002;1(13):1229-36
34. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell 2013;155(2):462-77
35. Dong H, Luo L, Hong S, et al. Integrated analysis of mutations, miRNA and mRNA expression in glioblastoma. BMC Syst Biol 2010;4:163
36. Polisetty RV, Gautam P, Sharma R, et al. LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signaling and other protein groups of regulatory functions. Mol Cell Proteomics 2012; 11(6):M111 013565
37. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014;505(7484):495-501
38. Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 1990;87(21):8602-6
39. Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J 2013;280(21):5350-70
40. Choe G, Horvath S, Cloughesy TF, et al. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003;63(11): 2742-6
41. Bonavia R, Inda MM, Vandenberg S, et al. EGFRvIII promotes glioma angiogenesis and growth through the NF-kappaB, interleukin-8 pathway. Oncogene 2012; 31(36):4054-66
42. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003
43. Kim YS, Kim SH, Cho J, et al. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: A single-institution study. Int J Radiat Oncol Biol Phys 2012; 84(3):661-7
44. Baldewpersad Tewarie NM, Burgers IA, Dawood Y, et al. NADP+ -dependent IDH1 R132 mutation and its relevance for glioma patient survival. Med Hypotheses 2013;80(6):728-31
45. Molenaar RJ, Verbaan D, Lamba S, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol 2014. [Epub ahead of print] for GBM survival
46. Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013; 81(17):1515-22
47. Cho WC. Circulating microRNAs as minimally invasive biomarkers for cancer theragnosis and prognosis. Front Genet 2011;2:7
48. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010;42(8):1273-81
49. Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One 2011;6(3):e17438
50. Karsy M, Arslan E, Moy F. Current progress on understanding MicroRNAs in glioblastoma multiforme. Genes Cancer 2012;3(1):3-15
51. Sana J, Hajduch M, Michalek J, et al. MicroRNAs and glioblastoma: roles in core signalling pathways and potential clinical implications. J Cell Mol Med 2011;15(8): 1636-44
52. Nikaki A, Piperi C, Papavassiliou AG. Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Expert Opin Investig Drugs 2012; 21(10):1475-88
53. Moller HG, Rasmussen AP, Andersen HH, et al. A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol 2013;47(1):131-44
54. Wang H, Hanash SM. Contributions of proteome profiling to the molecular analysis of cancer. Technol Cancer Res Treat 2002; 1(4):237-46
55. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008;27(45): 5904-12
56. Deighton RF, McGregor R, Kemp J, et al. Glioma pathophysiology: insights emerging from proteomics. Brain Pathol 2010;20(4): 691-703
57. Niclou SP, Fack F, Rajcevic U. Glioma proteomics: status and perspectives. J Proteomics 2010;73(10):1823-38
58. Iwadate Y, Sakaida T, Hiwasa T, et al. Molecular classification and survival prediction in human gliomas based on proteome analysis. Cancer Res 2004;64(7): 2496-501
59. Khalil AA. Biomarker discovery: A proteomic approach for brain cancer profiling. Cancer Sci 2007;98(2):201-13
60. Chumbalkar VC, Subhashini C, Dhople VM, et al. Differential protein expression in human gliomas and molecular insights. Proteomics 2005;5(4):1167-77
61. Melchior K, Tholey A, Heisel S, et al. Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatographyand mass spectrometry-based approaches. J Proteome Res 2009;8(10):4604-14
62. Polisetty RV, Gautam P, Gupta MK, et al. Heterogeneous nuclear ribonucleoproteins and their interactors are a major class of deregulated proteins in anaplastic astrocytoma: A grade III malignant glioma. J Proteome Res 2013;12(7):3128-38
63. Kozuka-Hata H, Nasu-Nishimura Y, Koyama-Nasu R, et al. Phosphoproteome of human glioblastoma initiating cells reveals novel signaling regulators encoded by the transcriptome. PLoS One 2012;7(8):e43398
64. Wolburg H, Noell S, Fallier-Becker P, et al. The disturbed blood-brain barrier in human glioblastoma. Mol Aspects Med 2012; 33(5-6):579-89
65. Reynes G, Vila V, Martin M, et al. Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma. J Neurooncol 2011; 102(1):35-41
66. Jung CS, Foerch C, Schanzer A, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 2007; 130(Pt 12):3336-41
67. Sreekanthreddy P, Srinivasan H, Kumar DM, et al. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 2010;19(6):1409-22
68. Kumar DM, Thota B, Shinde SV, et al. Proteomic identification of haptoglobin alpha2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth. J Proteome Res 2010;9(11): 5557-67
69. Petrik V, Saadoun S, Loosemore A, et al. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem 2008;54(4):713-22
70. Zougman A, Pilch B, Podtelejnikov A, et al. Integrated analysis of the cerebrospinal fluid peptidome and proteome. J Proteome Res 2008;7(1):386-99
71. Schutzer SE, Liu T, Natelson BH, et al. Establishing the proteome of normal human cerebrospinal fluid. PLoS One 2010;5(6): e10980
72. Khwaja FW, Reed MS, Olson JJ, et al. Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 2007;6(2):559-70
73. Ohnishi M, Matsumoto T, Nagashio R, et al. Proteomics of tumor-specific proteins in cerebrospinal fluid of patients with astrocytoma: usefulness of gelsolin protein. Pathol Int 2009;59(11):797-803
74. Schuhmann MU, Zucht HD, Nassimi R, et al. Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme. Eur J Surg Oncol 2010;36(2): 201-7
75. Zupancic K BA, Herman A, et al. Identification of plasma biomarker candidates in glioblastoma using an antibody-Array-based proteomic approach. Radiol Oncol 2014. [Epub ahead of print]
76. Formolo CA, Williams R, Gordish-Dressman H, et al. Secretome signature of invasive glioblastoma multiforme. J Proteome Res 2011;10(7): 3149-59
77. Demory Beckler M, Higginbotham JN, Franklin JL, et al. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol Cell Proteomics 2013; 12(2):343-55
78. Kucharzewska P, Christianson HC, Welch JE, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci USA 2013;110(18):7312-17
79. Silva J, Garcia V, Rodriguez M, et al. Analysis of exosome release and its prognostic value in human colorectal cancer. Genes Chromosomes Cancer 2012;51(4): 409-18
80. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10(12):1470-6
81. Petricoin EF, Belluco C, Araujo RP, Liotta LA. The blood peptidome: A higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 2006; 6(12):961-7
82. Geho DH, Liotta LA, Petricoin EF, et al. The amplified peptidome: the new treasure chest of candidate biomarkers. Curr Opin Chem Biol 2006;10(1):50-5
83. Weller M, Pfister SM, Wick W, et al. Molecular neuro-oncology in clinical practice: A new horizon. Lancet Oncol 2013;14(9):e370-9
84. Ichimura K, Pearson DM, Kocialkowski S, et al IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 2009;11(4):341-7
85. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 2009; 15(19):6002-e
86. Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Mod Pathol 2013;26(7):922-9
87. Wang Z, Bao Z, Yan W, et al. Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type. J Exp Clin Cancer Res 2013;32(1):59
88. Combs SE, Rieken S, Wick W, et al Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? Radiat Oncol 2011;6:115
89. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010;20(1):245-54
90. Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 2011;20(6):810-17
91. Cooper LA, Gutman DA, Long Q, et al. The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One 2010;5(9):e12548
92. Bambury RM, Morris PG. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme. Expert Rev Anticancer Ther 2014;1-10; [Epub ahead of print]
93. Stastna M, Van Eyk JE. Secreted proteins as a fundamental source for biomarker discovery. Proteomics 2012;12(4-5):722-35
94. López E, Madero L, Melén GJ. Clinical proteomics in cancer research. Curr Proteomics 2013;10(2):179-91
95. Ivanov AA, Khuri FR, Fu H. Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol Sci 2013;34(7): 393-400
96. Boisselier B, Gallego Perez-Larraya J, Rossetto M, et al. Detection of IDH1 mutation in the plasma of patients with glioma. Neurology 2012;79(16): 1693-8
97. Balana C, Ramirez JL, Taron M, et al. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1, 3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003;9(4): 1461-8
98. Salkeni MA, Zarzour A, Ansay TY, et al. Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. J Neurooncol 2013;115(1):27-35
99. Spellman PT, Gray JW. Detecting cancer by monitoring circulating tumor DNA. Nat Med 2014;20(5):474-5
100. Vos MJ, Postma TJ, Martens F, et al. Serum levels of S-100B protein and neuron-specific enolase in glioma patients: A pilot study. Anticancer Res 2004;24(4): 2511-14
101. Sampath P, Weaver CE, Sungarian A, et al. Cerebrospinal fluid (vascular endothelial growth factor) and serologic (recoverin) tumor markers for malignant glioma. Cancer Contr 2004;11(3):174-80
102. Zheng PP, Hop WC, Sillevis Smitt PA, et al. Low-molecular weight caldesmon as a potential serum marker for glioma. Clin Cancer Res 2005;11(12):4388-92
103. Elstner A, Stockhammer F, Nguyen-Dobinsky TN, et al. Identification of diagnostic serum protein profiles of glioblastoma patients. J Neurooncol 2011; 102(1):71-80
104. Ilzecka J, Ilzecki M. APRIL is increased in serum of patients with brain glioblastoma multiforme. Eur Cytokine Netw 2006; 17(4):276-80
105. Wrensch M, Wiencke JK, Wiemels J, et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res 2006;66(8):4531-41
106. Nano R, Capelli E, Argentina F, et al. Evaluation of serum levels of cytokines and intercellular adhesion molecule-1 (ICAM-1) in astrocytic tumours. Cell Mol Biol (Noisy-le-grand) 2003;49(4):525-8
107. Ammirati M, Rao S, Granger G. Detection of TNF inhibitors (soluble receptors) in the sera and tumor cyst fluid of patients with malignant astrocytomas of the brain. Front Biosci 2001;6:B17-24
108. Alper O, Stetler-Stevenson WG, Harris LN, et al. Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci 2009; 100(9):1748-56
109. Hormigo A, Gu B, Karimi S, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 2006; 12(19):5698-704
110. Crocker M, Ashley S, Giddings I, et al. Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro Oncol 2011;13(1): 99-108
111. Iwadate Y, Hayama M, Adachi A, et al. High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas. Anticancer Res 2008; 28(1B):415-18
112. Fukuda ME, Iwadate Y, Machida T, et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res 2005;65(12):5190-4
113. Taomoto K, Kokunai T, Okuda T, et al. [The value of neuron specific enolase (NSE) in patients with brain tumors]. No To Shinkei 1987;39(2):169-73
114. Quaranta M, Divella R, Daniele A, et al. Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. Tumori 2007;93(3):275-80
115. Zheng X, Chang F, Zhang X, et al. G-protein coupled receptor-Associated sorting protein 1 (GASP-1), a ubiquitous tumor marker. Exp Mol Pathol 2012;93(1): 111-15
116. Lin Y, Jiang T, Zhou K, et al. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol 2009;11(5):468-76
117. Reddy PS, Umesh S, Thota B, et al. PBEF1/NAmPRTase/Visfatin: A potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther 2008;7(5):663-8
118. Todaro L, Christiansen S, Varela M, et al. Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol 2007;83(2):135-44
119. Kandasamy K, Mohan SS, Raju R, et al. NetPath: A public resource of curated signal transduction pathways. Genome Biol 2010; 11(1):R3